Ticagrelor 60 vs. 90 mg in elderly acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI): a randomized, crossover trial
Primary result · PRUResult — go to the resultLeast squares mean difference −4 95% CI −16.27 to 8.06Authors' conclusion
Although plasma concentrations were lower, ticagrelor 60 mg twice daily provided a similar magnitude of platelet inhibition compared with ticagrelor 90 mg twice daily among elderly patients undergoing PCI.
Study context
- Population
- Elderly patients (≥75 years) with ACS undergoing PCI
- Participants
- 50 patients
- Comparison
- Ticagrelor 60 mg vs 90 mg twice daily
- Primary endpoint
- P2Y12 inhibition by pre-dose P2Y12 reaction units (PRU) (VerifyNow-P2Y12)
Methodological detailscrossover, non-inferiority
- Crossover
- Non-inferiority
Primary result
PRU
Least squares mean difference
−4
95% CI −16.27 to 8.06
P = 0.002 for non-inferiority
By group
Ticagrelor 60 mgvs Ticagrelor 90 mg
least squares mean difference −4 (95% CI −16.27 to 8.06); P for non-inferiority = 0.002
As reported in the abstract
Further findings
Plasma ticagrelor level
P = 0.006
Other pharmacodynamic parameters and response to aspirin
- Other pharmacodynamic parameters similar between doses; no differences in response to aspirin
Plasma ticagrelor level
- Active metabolite levels significantly lower with 60 mg
Original publication
Ticagrelor 60 vs. 90 mg in elderly ACS patients undergoing PCI: a randomized, crossover trial. Eur Heart J Cardiovasc Pharmacother. Published 18 July 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →